


Objectives

The objective of the Plurimi US Quality Growth Derivative Strategy is to achieve consistent returns through investments in cash, bonds, equity derivatives (short positions) and equity positions. The strategy is generally allocated to cash, with short put options on quality growth companies used to generate a premium and create a buying discipline on stocks at levels below current prices. Stock selection is aided by artificial intelligence with machine learning techniques.

Risk and return targets

- Typical beta: 0.2 (Can rise towards 1 in equity selloffs)
- Beta range 0.0-1.0
- Return target: US Libor +4% per annum

Total return (%) Simulated Strategy Model returns from inception



Total return in USD terms. (June 26 2023 – November 30 2024). These are simulated model portfolio returns, which are gross of trading commissions and do not reflect the deduction of investment management fees, which will reduce return. Source: Plurimi Wealth Bloomberg

Monthly model performance (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2024 USQG	+0.7	+1.0	+0.9	+1.0	+2.3	+1.4	+0.3	+1.1	+0.7	+0.8	+1.6		+12.8
S&P 500	+1.7	+4.8	+3.8	+5.0	+3.6	+1.2	+3.8	+2.4	+2.1	+1.1	+6.0		+28.0
2023 USQG						+0.8	+1.3	+0.9	-0.1	+0.5	+2.6	+1.0	+6.6
S&P 500						+2.7	+3.2	-1.5	-4.9	-2.1	+9.1	+4.5	+11.0

Total return in USD terms. (June 26, 2023 – November 30 2024). These are simulated model portfolio returns, which are gross of trading commissions and do not reflect the deduction of investment management fees, which will reduce return. Source: Plurimi Wealth Bloomberg

Sector exposure (%) on notional of Derivatives

	USQG	S&P 500	+/-
Communication Services	17.6	8.6	9.0
Consumer Discretionary	5.9	10.0	-4.1
Consumer Staples	11.8	6.2	5.6
Energy	0.0	3.3	-3.3
Financials	11.7	13.1	-2.4
Health Care	11.7	12.2	-0.5
Industrials	5.9	8.4	-2.5
Information Technology	35.3	31.0	4.3
Materials	0.0	2.2	-2.2
Real Estate	0.0	2.5	-2.5
Utilities	0.0	2.5	-2.5

Monthly

Top contributors	Contribution
SPDR 1-3 MONTH T-Bill	0.4
DIS 11/15/24 P93	0.2
ZTS 01/17/25 P65	0.1
ADBE 12/20/24 P450	0.1
META 01/17/25 p480	0.1

Bottom contributors	Contribution
LLY 11/15/24 P750	-0.2
GOOGL 01/17/25 P160	-0.1
CRM 11/15/24 P220	-0.0
LMT 11/15/24 P410	-0.0

Key points

Portfolio characteristics skewed towards high quality, and growth stocks. Stock selection aided by Plurimi Artificial Intelligence (AI) and machine learning process. Consistent and predictable income generated from option premia and cash positions. The strategy is moderately bullish and should perform well in rising, flat and moderately lower equity markets. In large equity drawdowns the strategy will own equity positions as these positions are put on the strategy.

Key risks

Capital is at risk. The use of derivatives may cap the upside of the strategy. The strategy is a focused portfolio, with significant stock specific risk. The strategy often exhibits low volatility, but individual equities are volatile and the positions in the strategy have equity like downside risk. The strategy takes significant sector differences from the benchmark which are intended to improve returns but can lead to capital loss. As equity markets fall, the equity exposure of strategy increases and decreases and equities rise.

Relative risk vs S&P 500 (ex-ante)

Delta (%)	0.2
Theta	0.2
Vega	-0.4
Beta	0.2

Performance indicators (%)

	USQG	SP 500
Annualised return	12.9	25.8
Annualised volatility	2.9	14.1
Sharpe ratio	2.7	1.6
Best month	2.6	9.1
Worst month	-0.1	-4.9
Max drawdown	-1.6	-10.0

Holdings

	(%)
T-Bill-3 MONTH ETF	96.10
Eli Lilly	5.15
AAPL US 12/20/24 P190	0.00
AMZN US 04/17/25 P195	0.00
CRM US 01/17/25 P260	-0.01
MSFT US 01/17/25 P400	-0.01
MDLZ US 01/17/25 P60	-0.01
CRM US 01/17/25 P250	-0.01
GOOGL US 01/17/25 P145	-0.02
LMT US 03/21/25 P460	-0.02
GOOGL US 01/17/25 P160	-0.02
BLK US 01/17/25 P890	-0.02
MSFT US 01/17/25 P390	-0.03
LLY US 09/19/25 P730	-0.03
LMT US 03/21/25 P440	-0.04
ADBE US 12/20/24 P450	-0.05
KO US 02/21/25 P60	-0.06
ZTS US 01/17/25 P165	-0.07
META US 03/21/25 P480	-0.12
MDLZ US 01/17/25 P65	-0.12
AVGO US 01/17/25 P140	-0.12
AMZN US 04/17/25 P185	-0.18
DIS US 08/15/25 P100	-0.19
NVDA US 03/21/25 P110	-0.21
LLY US 12/20/24 C750	-0.36

Source: Bloomberg/PW

Commentary

The strategy was up by 1.6% in November, which compares to the 6.0% return from the S&P 500.

The T-bill position rose 0.4% in November.

Eli Lilly was exercised against our position at \$750 on 15th of November. We sold a covered December \$750 call option on the stock during the month. Most positions delivered positive contributions, as the market moved higher and implied volatility dropped.

Apart from Eli Lilly, Alphabet, Salesforce and Lockheed Martin also delivered negative contributions.

We did not change any of the underlying stocks on which we wrote put options during the month.

Strategy managers:

Patrick Armstrong, CFA
Eugen Fostiak

Target return: Cash + 4% per annum
Positions: 2 Long, 17 Short.

Minimum investment: \$10 million

Definition of Terms:

Delta: Estimate of how much an option's value may change given a 1% move up or down in the underlying security. Short put options have a positive delta, meaning lower equity prices are negative for existing positions.

Vega: The amount an option's price is expected to change for a 1% change in implied volatility. Short option positions have a negative Vega, meaning higher implied volatility is negative for existing positions.

Theta: Theta refers to the rate of decline in the value of an option over time. Short option positions have a positive theta, meaning as time passes the option value decreases.

DISCLAIMER

The information and opinions expressed in this publication were produced by Plurimi Wealth LLP (Plurimi). This publication is intended for information purposes only and does not constitute an offer, a recommendation or an invitation by, or on behalf of Plurimi to make any investments. Opinions and comments of the authors reflect their current views, but not necessarily of other Plurimi entities or any other third party. This publication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, an investor should consider the suitability of the transaction against their individual circumstances and objectives. Any investment or trading or other decision should only be made after a review of the relevant product term sheet, subscription agreement, information memorandum, prospectus or other offering document relating to the issue of the securities or other financial instruments. Nothing in this publication constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate for an investor's circumstances, or otherwise constitutes a personal recommendation for any specific investor. Plurimi recommends that you independently assess, with a professional advisor, the specific financial risks as well as legal, regulatory, credit, tax and accounting consequences. Past performance is not a reliable indicator of future results. Performance forecasts are not a reliable indicator of future performance. An investor may not get back the amount invested or may be required to pay more. Although the information and data herein are obtained from sources believed to be reliable, no representation is made that the information is accurate or complete. Plurimi do not accept liability for any loss arising from the use of this publication. This publication cannot be reproduced or used for any other purpose and can only be distributed in countries where its distribution is legally permitted. This publication may relate to investments or services of an entity/person outside the UK, or to other matters which are not regulated by the FCA, or in respect of which the protections of the FCA for retail clients and/or the UK Financial Services Compensation Scheme may not be available. Further details as to where this may be the case are available on request in respect to this document, please contact your Plurimi Relationship Manager.

Plurimi Wealth LLP (No. OC326895) is a limited liability partnership incorporated in England and Wales with registered address: 30 St James's Square, London SW1Y 4AL, and is authorised and regulated by the Financial Conduct Authority (FCA).